Turkey: PIOZON Case Summary - 2012

Last Updated: 21 June 2016
Practice Guide by Deris IP Attorneys

PIOZON CASE SUMMARY

Jurisdiction: Turkey
Subject Heading: Similarity of Marks
Case Name and Citation:

MERCK KGAA vs THE TURKISH PATENT INSTITUTE&İSTANBUL GALENOS ECZ DEPOSU TİCARET VE SANAYİ AŞ,;
1- (4th Ankara Court of Intellectual and Industrial Rights, Case No. 2011/431- Decision No.2012/28, March 14, 2012)
2- (Supreme Court 11th Civil Chamber, Decision No: E.2009/13331- 2011/5967, May 16, 2011)

Plaintiff:

MERCK KGAA

Defendant:

1- THE TURKISH PATENT INSTITUTE
2- İSTANBUL GALENOS ECZ DEPOSU TİCARET VE SANAYİ AŞ

Marks Associated with Goods/Services:

The plaintiff has sought to register in Turkey the trademark PLIAZON through international application No: 826998 in respect of “Pharmaceutical preparations for human use in the field of oncology” in class 05.

The defendant (2) İSTANBUL GALENOS ECZ DEPOSU TİCARET VE SANAYİ AŞ is the registrant of the trademark reg. no: 2003/02736 for PIOZON trademark registered in respect of all goods in sub-classes of classes 05, 16 and 35.

Nature of Case:

The action has been instituted for the withdrawal of the final decision of the Turkish Patent Institute where the application of PLIAZON trademark was rejected due to prior registration for PIOZON trademark on the basis of undistinguishable similarity.

Prior Decisions:

The Defendant’s opposition against the publication of PLIAZON trademark application based on his prior PIZON trademark was accepted by the Turkish Patent Institute due to similarity of trademarks in the sense Article 8/1(b)1, Decree-Law no. 556 For Protection of Trademarks. Upon objection against this refusal decision Higher Council of the Turkish Patent Institute upheld that the trademarks in question are similar, accordingly the application of PLIAZON trademark would be rejected.

Overview of Decision and Ruling:

The plaintiff has asserted the following points in his petition:
- The importance of consumers which the trademarks address is an essential point in the evaluation of the similarity
- The applied PLIAZON trademark is the name of a drug which would be used in the treatment of cancer and therefore does have to be sold with prescription necessarily
- ZON indication has a weak distinctive character, therefore the holder of a trademark which is bearing such an indication must bear the consequences of it.
- The usage are of the trademarks in question namely the drugs are different
and requested the cancellation of the Higher Council Decision ruling that the PLIAZON and PIOZON trademarks are indistinguishably similar to each other.

The First defendant THE TURKISH PATENT INSTITUTE’s petition against the above assertions has been motivated in that:
- The trademarks in question are similar to each other in the sense of Article 8/b(1)
- The specifications covered by the trademarks are identical and similar
- The similarity does not arise from a use of an active substance of the drugs in question as an indication
- The trademarks in question may lead even the doctors and pharmacist who do pay high attention to confusion
therefore the prior decision of Higher Council is well-grounded and the present case must be rejected.

The second defendant GALENOS put forward in his petition that:
- The trademark of the plaintiff is indistinguishably similar to his prior trademark due to covering same specifications
- The similarity between trademarks may lead the consumers to confusion, therefore there is likelihood of confusion.

In the light of the evidences submitted by the parties and of the experts report which are in plaintiff’s favor, The 1st Instance Court contrary to the conclusions of the Experts report retained that:
- since the PLIAZON trademark is applied for “Pharmaceutical preparations for human use in the field of oncology” goods in class 05 and the prior PIOZON trademark is registered in all sub-classes of 05, 16 and 35, the trademarks overlaps in the first sub-classes of class 05.
- the trademarks in question are not identical but similar in the sense of Article 8/1(b) in respect of visual and phonetic aspects due to common initial P letter and last three ZON letters as well as two letter difference of L and A.
- the consumers may consider that the trademarks belong to the same or associated company
- even though PLIAZON trademark is applied for the “Pharmaceutical preparations for human use in the field of oncology”, it has revealed that there is no application for any regulatory authorization for both PLIAZON and PIOZON trademarks before the Ministry of Health, accordingly the active ingredients of the drugs are not known. Moreover, the PIOZON trademark is registered for the all sub-classes in class 05, it was not determined that on which drugs the trademark would be used.
- despite the fact that the trademarks used on drugs are firstly subject to authorization by the Ministry of Health and then sold through pharmacists upon prescription written by doctors, there is no special regulation or provision for this practice in the Article 8/b of the Decree-Law no. 556 for the protection of the trademarks, so this fact can not be a point to be taken into consideration for assessing similarity.
- the ZON indication is not a weak indication since such a weakness is only acceptable on the condition that a trademark consist of an indication which indicates an active substance in the drug.
- to oblige the doctors, pharmacist and the patients to pay high attention in distinguishing the trademarks does not comply with the “distinctiveness” function of the trademark while there are no technical necessities and there are many options in choosing another distinctive indication.
and ruled that there is likelihood of confusion between the trademarks PLIAZON and PIOZON thus upholding the TPI’s decision of refusal.

The decision was appealed by the plaintiff and the Supreme Court with its decision (2) overturned the decision of the 1st Instance Court on grounds that:
- since PLIAZON trademark would be used on drugs used in the treatment of cancer, it is not possible for such a drug to be sold without control of doctor and without prescription. In this respect its use can not be subject to same conditions as for non-prescription drugs.
- In accordance with the above-mentioned point, it was determined in two experts reports that there is no likelihood of confusion between the trademarks in taking into account the involvement of doctors and pharmacists in the choice and use of the drugs under the trademark PLIAZON.

Upon the reverse of the judgment, the First Instant Court upheld in compliance with the Supreme Court decision and ruled the cancellation of subject Higher Council decision and the continuation of the application process of PLIAZON trademark since there is not a indistinguishable similarity between PLIAZON and PIOZON trademark.

Importance of Case:

This case is important because according to the current practice of Turkish Trademark Law, similarity of goods and services is evaluated on the basis of sub-classes. In other words, even though the goods and services are different, they are deemed similar in case they fall under the same subclasses. With this decision, the Court ruled that even though the goods of PLIAZON trademark, “Pharmaceutical preparations for human use in the field of oncology” fall under the first sub-class of class 05 which was covered wholly by PIOZON trademark, the goods of the trademark must not be evaluated as similar considering the fact that the drugs for treatment of cancer can only be bought upon prescription written by doctors.


1 Upon opposition by the proprietor of an application for registration of a trademark or of a registered trademark, the trademark applied for shall not be registered subject to the following conditions:

b)Where the trademark applied for is identical or similar to a registered trademark or to a trademark applied for registration under a prior date of filing and the registration is sought for identical or similar goods or services in that the likelihood of confusion includes the likelihood of association with the registered trademark or with the trademark applied for registration under a prior date of filing.

This document is not intended to create an attorney-client relationship. You should not act or rely on any information in this document without first seeking legal advice. This material is intended for general information purposes only and does not constitute legal advice. If you have any specific questions on any legal matter, you should consult a professional legal services provider.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Contact the Author?
Click here to email the Author
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Other Turkey Advice Centres
Competition and Antitrust
Tax
Privacy and Data Protection
More Advice Centers
Useful Resources
Translation by Deris Patents & Trademarks Agency Limited
Translation by Deris Patents & Trademarks Agency Limited
Translation by Deris Patents & Trademarks Agency Limited
Translation by Deris Patents & Trademarks Agency Limited
The national Turkey group for the International Association for the Protection of Intellectual Property.
Upcoming Events
This site provides access to information about meetings held at WIPO and related documents comprising a detailed meeting calendar and a powerful document search facility.
A calendar of past and future events held by the Turkish Patent Institute.
Information about events and classroom training, online training, the European qualifying examination, and other materials.
From the Annual Meeting to local forums, roundtables and digital learning, INTA's Programs and Events help you stay up to date on issues that affect your brands.
Tools
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.